WO1987003374A1 - Antibody detection - Google Patents

Antibody detection Download PDF

Info

Publication number
WO1987003374A1
WO1987003374A1 PCT/GB1986/000724 GB8600724W WO8703374A1 WO 1987003374 A1 WO1987003374 A1 WO 1987003374A1 GB 8600724 W GB8600724 W GB 8600724W WO 8703374 A1 WO8703374 A1 WO 8703374A1
Authority
WO
WIPO (PCT)
Prior art keywords
ussn
virus
zone
filter
reaction zone
Prior art date
Application number
PCT/GB1986/000724
Other languages
French (fr)
Inventor
Dinesh Andrew Jacob
Gwynfor Rees Williams
Original Assignee
Murex Medical Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858529067A external-priority patent/GB8529067D0/en
Priority claimed from GB858529276A external-priority patent/GB8529276D0/en
Priority claimed from US06/857,914 external-priority patent/US4693834A/en
Application filed by Murex Medical Research Limited filed Critical Murex Medical Research Limited
Publication of WO1987003374A1 publication Critical patent/WO1987003374A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/549—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic with antigen or antibody entrapped within the carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Definitions

  • This invention relates to detection of antibodies to the AIDS virus.
  • AIDS has become a worldwide problem over a short time. The problem is only likely to increase in the foreseeable future. There is apparently no cure at present, but spread of the disease could be contained, e.g. until a cure is found, by quick and accurate diagnosis of potential carriers.
  • a subject can usefully be tested by analysis of plasma, serum or another liquid sample, for the presence of antibodies to the virus.
  • a summary of the prior art is given in the parent specification.
  • SUMMARY OF THE INVENTION A device of the type fully described, claimed and illustrated in the parent specification has AIDS antigen immobilised on the filter material therein and is used for testing for antibodies to the AIDS virus in a liquid sample.
  • a filter material has antigen immobilised in a reaction zone thereof, the liquid sample is applied on to the reaction zone and allowed to flow through the filter material where it is taken up by absorbent material disposed in contact with the filter material.
  • the device which is preferably used in the invention comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter.
  • a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter.
  • the specimen is introduced on to the reaction zone of the filter through the aperture, suitably by flow under gravity, and is taken up in the absorbent means/material.
  • the filter material By having coated or impregnated the filter material with antigen in the reaction zone, antigen-antibody reaction products remain in the filter, after passage of the specimen and washing as necessary. These products can then be visualised or otherwise tested in conventional manner.
  • virus or virus particles are immobilised on latex microparticles or other particles or in the filter material. Owing to the cytotropic nature of AIDS-causing virus or other agent such as HTLV-III, lymphadenopathy virus or AIDS-associated retrovirus, it may be provided on infected T lymphocytes or any other eukaryotic or prokaryotxc cells, or antigen derived from
  • Serum under test is then added, possibly containing anti-HTLV, followed by 5 anti-globulin, e.g. anti-human IgG, enzyme-labelled.
  • viral DNA e.g. HTLV-DNA
  • labelled hydridising DNA can be used to probe DNA exposed by lysis of a clinical sample on the substrate. 10 Washing is conducted as necessary, e.g. between each step as described above. Bound labelled reactant can be visualised in conventional manner, in order to determine the presence of antibody bound to antigen in the reaction zone. 15

Abstract

A process for testing for antibodies to the AIDS virus in a liquid sample, which comprises applying the sample on to a zone of a filter material, the zone having AIDS virus or virus particles immobilised therein, and allowing the liquid to pass through the filter material and to be taken up by absorbent material in contact therewith.

Description

ANTIBODY DETECTION RELATION TO EARLIER APPLICATIONS
This application is related, inter alia, to the following five patent applications:
(1) USA, Serial No. 740,100, filed 3,1st May 1985;
(2) USA, Serial No. 857,914, filed 5th May 1986;
(3) Europe, No. 86304147.1, filed 30th May 1986, published as EP-A-0206561; (4) Canada, No. 510,307, filed 29th May 1986; and (5) Japan, No. (not yet known) , filed ? May 1986. The specifications of 2, 3, 4 and 5 (including the drawings) are essentially the same and are incorporated herein by reference; that subject matter is hereinafter described as "the parent specification". 3 and 5 are filed in the name of Murex Corporation, claiming priority from 1 and 2. Dinesh Andrew Jacob and Miles Gerald
Hossom are named as the inventors.
FIELD OF THE INVENTION This invention relates to detection of antibodies to the AIDS virus.
BACKGROUND OF THE INVENTION
AIDS has become a worldwide problem over a short time. The problem is only likely to increase in the foreseeable future. There is apparently no cure at present, but spread of the disease could be contained, e.g. until a cure is found, by quick and accurate diagnosis of potential carriers.
A subject can usefully be tested by analysis of plasma, serum or another liquid sample, for the presence of antibodies to the virus.
PRIOR ART
A summary of the prior art is given in the parent specification. SUMMARY OF THE INVENTION A device of the type fully described, claimed and illustrated in the parent specification has AIDS antigen immobilised on the filter material therein and is used for testing for antibodies to the AIDS virus in a liquid sample.
In general terms, a filter material has antigen immobilised in a reaction zone thereof, the liquid sample is applied on to the reaction zone and allowed to flow through the filter material where it is taken up by absorbent material disposed in contact with the filter material. DETAILED DESCRIPTION OF THE INVENTION
The device which is preferably used in the invention comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter. Such a device is fully described and illustrated in the parent specification.
In a process according to the invention, the specimen is introduced on to the reaction zone of the filter through the aperture, suitably by flow under gravity, and is taken up in the absorbent means/material. By having coated or impregnated the filter material with antigen in the reaction zone, antigen-antibody reaction products remain in the filter, after passage of the specimen and washing as necessary. These products can then be visualised or otherwise tested in conventional manner.
By way of example, virus or virus particles are immobilised on latex microparticles or other particles or in the filter material. Owing to the cytotropic nature of AIDS-causing virus or other agent such as HTLV-III, lymphadenopathy virus or AIDS-associated retrovirus, it may be provided on infected T lymphocytes or any other eukaryotic or prokaryotxc cells, or antigen derived from
A gene-cloning, which are immobilised. Serum under test is then added, possibly containing anti-HTLV, followed by 5 anti-globulin, e.g. anti-human IgG, enzyme-labelled.
Alternatively, viral DNA, e.g. HTLV-DNA, is used, and can be probed with complementary labelled DNA. Again, labelled hydridising DNA can be used to probe DNA exposed by lysis of a clinical sample on the substrate. 10 Washing is conducted as necessary, e.g. between each step as described above. Bound labelled reactant can be visualised in conventional manner, in order to determine the presence of antibody bound to antigen in the reaction zone. 15
20
25
30 *s
35

Claims

1. A process for testing for antibodies to the AIDS virus in a liquid sample, which comprises applying the sample on to a zone of a filter material, the zone having AIDS virus or virus particles immobilised therein, and allowing the liquid to pass through the filter material and to be taken up by absorbent material in contact therewith.
2. A process according to claim 1, which comprises introducing, after the specimen, a labelled material which binds with the components in the specimen which have been immobilised on the filter.
3. A device which comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter; and in which AIDS virus or virus particles are immobilised in the reaction zone.
4. A process or device according to any preceding claim, wherein the virus or virus particles are carried on latex or other particles or on T-lymphocytes.
5. A process or device according to any of claims 1 to
4. wherein the device is as defined in claim 1 of USSN 857,914 or EP-A-0206561.
6. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 2 of USSN 857,914 or EP-A-0206561.
7. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 3 of USSN
857,914 or EP-A-0206561.
8. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 4 of USSN 857,914 or EP-A-0206561.
9. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 5 of USSN 857,914 or EP-A-0206561.
10. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 6 of USSN
_ 857,914 or EP-A-0206561.
11. A process or device according to any of claims 1 to 5 4, wherein the device is as defined in claim 7 of USSN
857,914 or EP-A-0206561.
12. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 8 of USSN 857,914 or EP-A-0206561.
10 13. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 9 of USSN 857,914 or EP-A-0206561.
14. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 10 of USSN
15 857,914 or EP-A-0206561.
15. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 11 of USSN 857,914 or EP-A-0206561.
16. A process or device according to any of claims 1 to 20 4, wherein the device is as defined in claim 12 of USSN
857,914 or EP-A-0206561.
17. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 13 of USSN 857,914 or EP-A-0206561.
25 18. A process or device according to any of, claims 1 to
4, wherein the device is as defined in claim 14 of USSN
857,914 or EP-A-0206561.
19. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 15 of USSN 30 857,914 or EP-A-0206561. '""
20. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 16 of USSN
857,914 or EP-A-0206561.
21. A process or device according to any of claims 1 to 35 4, wherein the device is as defined in claim 17 of USSN
857,914 or EP-A-0206561.
22. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 18 of USSN 857,914 or EP-A-0206561.
23. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 19 of USSN
857,914 or EP-A-0206561.
24. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 20 of USSN 857,914 or EP-A-0206561.
25. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 21 of USSN 857,914 or EP-A-0206561.
26. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 22 of USSN 857,914 or EP-A-0206561.
27. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 23 of USSN 857,914 or EP-A-0206561.
28. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 24 of USSN
857,914 or EP-A-0206561.
29. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 25 of USSN 857,914 or EP-A-0206561.
30. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 26 of USSN 857,914 or EP-A-0206561.
31. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 27 of USSN 857,914 or EP-A-0206561.
32. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 28 of USSN 857,914 or EP-A-0206561.
33. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 29 of USSN
857,914 or EP-A-0206561.
34. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim- 30 of USSN 857,914.
35. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 31 of USSN
857,914.
36. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 32 of USSN 857,914.
37. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 33 of USSN 857,914.
38. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 34 of USSN 857,914.
39. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 35 of USSN 857,914.
40. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 36 of USSN
857,914.
41. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 37 of USSN 857,914.
42. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 38 of USSN 857,914.
43. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 39 of USSN 857,914.
44. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 40 of USSN 857,914.
45. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 41 of USSN
857,914.
46. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 42 of USSN 857,914.
47. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 43 of USSN
857,914.
48. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 44 of USSN 857,914.
49. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 45 of USSN 857,914.
50. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 46 of USSN 857,914.
51. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 47 of USSN 857,914.
52. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 48 of USSN
857,914.
53. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 49 of USSN 857,914.
54. A process or device according to any of claims 1 to
4, wherein the device is as defined in claim 50 of USSN 857,914.
55. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 51 of USSN 857,914.
56. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 52 of USSN 857,914.
57. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 53 pf USSN
857,914.
58. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 54 of USSN 857,914.
59. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 55 of USSN
857,914.
60. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 56 of USSN 857,914.
61. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 57 of USSN 857,914.
62. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 58 of USSN 857,914.
63. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 59 of USSN 857,914.
64. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 60 of USSN
857,914.
65. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 61 of USSN 857,914.
66. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 62 of USSN 857,914.
67. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 63 of USSN 857,914.
68. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 64 of USSN 857,914.
69. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 65 of USSN
857,914.
70. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 66 of USSN 857,914.
71. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 67 of USSN
857,914.
PCT/GB1986/000724 1985-11-26 1986-11-26 Antibody detection WO1987003374A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB8529067 1985-11-26
GB858529067A GB8529067D0 (en) 1985-05-31 1985-11-26 Diagnosis
GB858529276A GB8529276D0 (en) 1985-11-28 1985-11-28 Diagnosis
GB8529276 1985-11-28
US06/857,914 US4693834A (en) 1986-05-05 1986-05-05 Transverse flow diagnostic kit

Publications (1)

Publication Number Publication Date
WO1987003374A1 true WO1987003374A1 (en) 1987-06-04

Family

ID=27262851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1986/000724 WO1987003374A1 (en) 1985-11-26 1986-11-26 Antibody detection

Country Status (2)

Country Link
EP (1) EP0247124A1 (en)
WO (1) WO1987003374A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010272A1 (en) * 1987-06-26 1988-12-29 Garth Alexander Nicholson Method of preserving a body fluid sample, prior to assay for hiv (aids) infection
US5077198A (en) * 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5268299A (en) * 1988-04-14 1993-12-07 Eastman Kodak Company Diluent composition useful in the detection of antibodies in assays
US5759774A (en) * 1988-05-18 1998-06-02 Cobe Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119623A2 (en) * 1983-03-17 1984-09-26 Fuji Photo Film Co., Ltd. Multilayer analytical element for non-isotopic assay
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
EP0173295A1 (en) * 1984-08-31 1986-03-05 New York Blood Center, Inc. Assay for simultaneous detection of antigen and antibody in given serum

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119623A2 (en) * 1983-03-17 1984-09-26 Fuji Photo Film Co., Ltd. Multilayer analytical element for non-isotopic assay
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
EP0173295A1 (en) * 1984-08-31 1986-03-05 New York Blood Center, Inc. Assay for simultaneous detection of antigen and antibody in given serum

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Analytical Chemistry, Volume 57, No. 7, June 1985, American Chemical Society, (Washington, DC, US), M.D.W.: "AIDS Antibody Screening Test", see pages 773A-778A *
Biotechnology, Volume 3, No. 10, October 1985, (New York, US), t.W. CHANG et al.: "Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a Recombinant Escherichia Coli-Derived Viral antigenic Peptide", pages 905-909, see page 908 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010272A1 (en) * 1987-06-26 1988-12-29 Garth Alexander Nicholson Method of preserving a body fluid sample, prior to assay for hiv (aids) infection
US5077198A (en) * 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5268299A (en) * 1988-04-14 1993-12-07 Eastman Kodak Company Diluent composition useful in the detection of antibodies in assays
US5759774A (en) * 1988-05-18 1998-06-02 Cobe Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells

Also Published As

Publication number Publication date
EP0247124A1 (en) 1987-12-02

Similar Documents

Publication Publication Date Title
EP0267317B1 (en) Method for the detection of proteins and viruses
US5571667A (en) Elongated membrane flow-through diagnostic device and method
AU614109B2 (en) Test method and reagent kit therefor
EP0595641A2 (en) One-step simultaneous immunoassay
EP0139389A1 (en) Antiidiotypic monoclonal antibody reagents and immunoassays employing antiidiotypic monoclonal antibody reagents
PL196464B1 (en) Neutralisation of polycations in chromatographic equipment used to analyse whole blood
JP3693680B2 (en) Assays using magnetic particles
JPS6126860A (en) Method and device for executing analysis measurement
CA2137786A1 (en) Immunoassay
JP3908272B2 (en) Solid phase assay for detection of ligands
EP2796880B1 (en) Platelet allo-antigen typing and platelet antibody tests
CA1170180A (en) Process for the enzyme immuno determination in the heterogenous phase
WO1987003374A1 (en) Antibody detection
EP0402023A1 (en) Elongated membrane flow-through diagnostic device and method
WO1987003373A1 (en) Virus detection
Olaussen et al. Screening tests for antinuclear antibodies (ANA): selective use of central nuclear antigens as a rational basis for screening by ELISA
JP2549305B2 (en) Independent multiplex immunoassay diagnostic system
AU2015213838B2 (en) Crossmatching blood samples
CN218331595U (en) IgG antibody subtype detection kit
JP3618797B2 (en) Immunoassay
CA2056278C (en) Washing solution, which contains a complexing agent for metal ions, for a solid-phase immunometric method, and the use thereof
JPH08114595A (en) Specific bonding measuring method
JPH06281652A (en) Detecting method of antibody and antigen
JPH02151769A (en) Reaction container
JPH08240592A (en) Method for preventing non-specific reaction in immunological inspection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986906897

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986906897

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986906897

Country of ref document: EP